A Clinically-Defined Multifunctional Bacterial Consortium for the Treatment of Ulcerative Colitis

Time: 11:50 am
day: Track B - Afternoon - Day One


  • Microbiotica possesses a unique analysis platform for the discovery of microbiome signatures from clinical data
  • Leveraging the power of the Microbiotica platform to analyse a unique FMT trial dataset in mild-to-moderate UC patients, a response signature has been identified for development into a multi-species consortium product – MB310
  • MB310 addresses multiple aspects of UC disease pathology at the cellular level